Kytopen, a Cambridge, Mass.-based tech startup accelerating the discovery and manufacturing of gene-modified cell therapies, raised $3.6m in seed financing.
Backers included The Engine, Horizons Ventures and angel investors.
The company intends to use the funds for the ongoing development of FlowfectTM.
Founded by Paulo Garcia, CEO, and Cullen Buie, Kytopen is developing FlowfectTM, a proprietary non-viral cell engineering platform which can process a therapeutic payload of cells in seconds by combining microfluidics and automation.
The Engine, the venture capital firm launched by MIT to invest in early-stage Tough Tech companies, had already invested in Kytopen’s pre-seed round in 2017.